Quantbot Technologies LP Makes New $345,000 Investment in Haemonetics Co. (NYSE:HAE)

Quantbot Technologies LP purchased a new position in shares of Haemonetics Co. (NYSE:HAE - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 4,415 shares of the medical instruments supplier's stock, valued at approximately $345,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Whittier Trust Co. purchased a new stake in shares of Haemonetics in the fourth quarter valued at about $62,000. Parkside Financial Bank & Trust boosted its holdings in Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares in the last quarter. AlphaQuest LLC grew its holdings in shares of Haemonetics by 36,520.0% in the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after acquiring an additional 1,826 shares during the period. KBC Group NV grew its holdings in Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after purchasing an additional 712 shares during the last quarter. Finally, iSAM Funds UK Ltd purchased a new position in Haemonetics during the 3rd quarter valued at about $204,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Stock Performance

NYSE:HAE traded up $1.07 during trading hours on Wednesday, reaching $64.09. 466,971 shares of the stock were exchanged, compared to its average volume of 666,914. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The stock has a market capitalization of $3.22 billion, a P/E ratio of 25.23, a P/E/G ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The firm has a 50 day simple moving average of $65.42 and a 200-day simple moving average of $74.47.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, sell-side analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on HAE. Raymond James reissued a "strong-buy" rating and set a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. JMP Securities decreased their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a report on Friday, February 7th. StockNews.com cut Haemonetics from a "buy" rating to a "hold" rating in a report on Saturday, February 15th. Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and lowered their price target for the company from $95.00 to $68.00 in a report on Friday, February 7th. Finally, Needham & Company LLC dropped their price objective on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Haemonetics currently has an average rating of "Moderate Buy" and a consensus price target of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.